PLCG2
PLCG2 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Chronic lymphocytic leukaemia.
Overview
The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. It is a crucial enzyme in transmembrane signalling.
CIViC holds 3 clinical evidence items and 0 assertions across 3 variants, naming Venetoclax.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PLCG2 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Chronic lymphocytic leukaemia.
- 1 · What it is
PLCG2 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Chronic lymphocytic leukaemia.
- 2 · What goes wrong in cancer
The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. It is a crucial enzyme in transmembrane signalling.
- 3 · How drugs use it
No product in this corpus aims at PLCG2 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:9066 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P16885 (protein name, function text, keywords and locations (REST API)); CIViC gene PLCG2 (3 evidence items, 0 assertions, 3 variants; diseases: Chronic Lymphocytic Leukaemia (GraphQL API, CC0))
Biology
The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. It is a crucial enzyme in transmembrane signalling. Location: Membrane raft (UniProt). Locus 16q24.1 (HGNC).
- Chronic lymphocytic leukaemia: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 3 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PLCG2" OR ABSTRACT:"PLCG2" OR TITLE:"phospholipase C gamma 2" OR ABSTRACT:"phospholipase C gamma 2" OR TITLE:"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2" OR ABSTRACT:"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PLCG2, not a curated reading list.